Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listEculizumab

Eculizumab

  • CAS NO.:219685-50-4
  • Molecular Weight: 0
  • Update Date: 2024-07-02 08:54:57

What is Eculizumab?

Description

Eculizumab, a fully humanized anti-C5 monoclonal antibody, was introduced for treating patients with PNH to reduce hemolysis. It is the first therapy to be approved for this rare and life-threatening form of hemolytic anemia. PNH is a clonal hematopoietic stem-cell disorder that is characterized by the production of abnormal red blood cells (RBCs) with a deficiency of surface proteins that protect the cells against attack by the body’s complement system. Complement-mediated destruction of the susceptible RBCs results in intravascular hemolysis, the primary clinical manifestation in all PNH patients. Previously, patients with PNH have mainly been managed supportively, with red cell transfusions as required, and treatments such as folate and iron supplementation, anticoagulation for thrombotic disease, and the occasional use of steroids during hemolytic crises. Allogenic stem cell transplantation is currently the only curative option for PNH; however, it is associated with significant morbidity and mortality. Eculizumab therapy is aimed at preventing red cell lysis through blockade of complement activation process and the production of the membrane attack complex. Eculizumab specifically binds to the human complement protein C5 with high affinity (IC50 = 2 nM) and inhibits its cleavage to C5a and C5b, which is a key step in the pathway leading to the membrane attack complex C5b-C9.
Eculizumab has been granted orphan drug status from both the FDA and European regulatory agencies.The most serious adverse reaction associated with eculizumab therapy is meningococcal infections. Eculizumab is contraindicated in patients who are not vaccinated against Neisseria meningitidis or who have N. meningitidis infections. The most common adverse reactions with eculizumab include headache (44%), nasopharyngitis (23%), back pain (19%), and nausea (16%).

Originator

Alexion (US)

The Uses of Eculizumab

Treatment of autoimmune disease such as rheumatoid arthritis, membranous nephritis, lupus nephritis, dermatomyositis, and autoimmune hemolytic anemias.

brand name

Soliris

General Description

Eculizumab (Soliris) is a monoclonal antibodythat binds to the terminal complement protein C5 inRBCs. This blocks the cleavage of C5 and halts the processof complement-mediated cell destruction of the RBCs.Eculizumab has been shown to be effective in treating PNHand in March 2007 was approved by the FDA for treatingPNH.

Clinical Use

Recombinant monoclonal antibody:
Paroxysmal nocturnal haemoglobinuria (PNH)
Atypical haemolytic uraemic syndrome (aHUS)
Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (MG)

Metabolism

Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolised by lysosomal enzymes to small peptides and amino acids.

Properties of Eculizumab

storage temp.  Store at -20°C
form  Liquid
color  Colorless to light yellow
CAS DataBase Reference 219685-50-4

Safety information for Eculizumab

Computed Descriptors for Eculizumab

Related products of tetrahydrofuran

You may like

  • 7726-95-6 Bromine 99.5% AR (4 x 500ml) 99%
    7726-95-6 Bromine 99.5% AR (4 x 500ml) 99%
    7726-95-6
    View Details
  • Formamide 99%
    Formamide 99%
    75-12-7
    View Details
  • 376608-65-0 2-[[(3Ar,4S,6R,6As)-6-Aminotetrahydro-2,2-Dimethyl-4H-Cy 99%
    376608-65-0 2-[[(3Ar,4S,6R,6As)-6-Aminotetrahydro-2,2-Dimethyl-4H-Cy 99%
    376608-65-0
    View Details
  • 2, 4-Pyrimidinediamine 3-Oxide 99%
    2, 4-Pyrimidinediamine 3-Oxide 99%
    74638-76-9
    View Details
  • 111974-72-2 99%
    111974-72-2 99%
    111974-72-2
    View Details
  • 85-81-4 6-Methoxy-8-Nitroquinoline 99%
    85-81-4 6-Methoxy-8-Nitroquinoline 99%
    85-81-4
    View Details
  • 3-Bromo-4,5-Dihydro-1H-Benzo[B]Azepin-2(3H)-One 99%
    3-Bromo-4,5-Dihydro-1H-Benzo[B]Azepin-2(3H)-One 99%
    86499-96-9
    View Details
  • (−)-Dip-Chloride 85116-37-6 99%
    (−)-Dip-Chloride 85116-37-6 99%
    85116-37-6
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.